Kaleb Yohay

Cognition and behavior in neurofibromatosis type 1: report and perspective from the Cognition and Behavior in NF1 (CABIN) Task Force

Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation

Management of neurofibromatosis type 1-associated plexiform neurofibromas

MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus

Management and surgical outcomes of dystrophic scoliosis in neurofibromatosis type 1: a systematic review

Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation

The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities

Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing <i>CLN2</i>

Clinical spectrum of individuals with pathogenic <i> <b>N</b> F1 </i> missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype–phenotype study in neurofibromatosis type 1

Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)

Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study

Comparison of hybrid 18F.fluorodeoxyglucose positron emission tomography/magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1

Creation of an international registry to support discovery in schwannomatosis

Long-Term Expression and Safety of Administration of AAVrh.10hCLN2 to the Brain of Rats and Nonhuman Primates for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis